Stereotaxis (AMEX:STXS) is gearing up to announce its quarterly earnings on Monday, 2026-03-09. Here's a quick overview of what investors should know before the release.

Analysts are estimating that Stereotaxis will report an earnings per share (EPS) of $-0.06.

Investors in Stereotaxis are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.

It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.

Historical Earnings Performance

The company's EPS missed by $0.01 in the last quarter, leading to a 14.74% drop in the share price on the following day.

Here's a look at Stereotaxis's past performance and the resulting price change:

Stereotaxis Share Price Analysis

Shares of Stereotaxis were trading at $2.19 as of March 05. Over the last 52-week period, shares are up 21.75%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Unveiling the Story Behind Stereotaxis

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

Breaking Down Stereotaxis's Financial Performance

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Challenges: Stereotaxis's revenue growth over 3 months faced difficulties. As of 30 September, 2025, the company experienced a decline of approximately -18.83%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Stereotaxis's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -90.9% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Stereotaxis's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -175.73%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Stereotaxis's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -15.64%, the company may face hurdles in achieving optimal financial performance.

Debt Management: Stereotaxis's debt-to-equity ratio is below the industry average at 0.89, reflecting a lower dependency on debt financing and a more conservative financial approach.

To track all earnings releases for Stereotaxis visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.